Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 13, 2024, titled "Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US.".